BIO-FD&C Co.,Ltd. (KOSDAQ:251120)
South Korea
· Delayed Price · Currency is KRW 14,430
-60 (-0.41%)
At close: Apr 28, 2026
BIO-FD&C Revenue
In the year 2025, BIO-FD&C had annual revenue of 19.18B KRW with 19.37% growth. BIO-FD&C had revenue of 5.10B in the quarter ending December 31, 2025, with 7.65% growth.
Revenue
19.18B
Revenue Growth
+19.37%
P/S Ratio
6.54
Revenue / Employee
n/a
Employees
n/a
Market Cap
125.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 19.18B | 3.11B | 19.37% |
| Dec 31, 2024 | 16.07B | 474.34M | 3.04% |
| Dec 31, 2023 | 15.59B | -263.23M | -1.66% |
| Dec 31, 2022 | 15.86B | 3.88B | 32.43% |
| Dec 31, 2021 | 11.97B | 3.33B | 38.57% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NovMetaPharma | 1.30B |
| CORESTEMCHEMON | 20.16B |
| Cell Biotech | 53.13B |
| CHA Vaccine Research Institute | 158.62M |
| KoBioLabs | 69.29B |
| TegoScience | 5.94B |
| SunBio,Inc. | 2.17B |
| QuadMedicine | 10.70B |